P-Co-Li (Pulmonary Covid-19 Study)
NCT04782700 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL
Last updated 2022-02-16
Summary
The aim of this study is to determine whether the use of steroids versus watchful waiting improves pulmonary function tests in patients with history of COVID 19 infection who have residual hypoxemia and lung infiltrates. This is a non-inferiority trial which tests whether the outcomes after watchful waiting are not worst than after the use of steroids, with a margin of acceptable inferiority. The study team will limit inclusion to patients who have PCR- confirmed COVID19 at least in 10-weeks prior to enrollment, persistent opacities on chest imaging, and hypoxemia either at rest or during ambulation.
Conditions
- Covid19
- Lung Inflammation
- Hypoxemic Respiratory Failure
Interventions
- OTHER
-
Steroid Taper (Prednisone)
The patients randomized to the steroid group will be prescribed prednisone PO or an equivalent corticosteroid at a dose of 0.5 mg/kg/day for 4 weeks ((plus BACTRIM-DS (1PO qd. 160/800mg) as prophylaxis against infection - If patient have a sulfa allergy, their physician will prescribe atovaquone 1500mg qd instead of Bactrim) and followed by a gradual taper of 0.25 mg/kg/day for 4 weeks, followed by 0.125 mg/kg qd for 4 weeks.
Sponsors & Collaborators
-
Northwell Health
lead OTHER
Principal Investigators
-
Negin Hajizadeh, MD · Northwell Health
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-04-01
- Primary Completion
- 2021-06-08
- Completion
- 2021-06-08
Countries
- United States
Study Locations
More Related Trials
-
Efficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 Pneumonia
NCT04359511 ·Status: WITHDRAWN ·Phase: PHASE3
-
The Procalcitonin Guided Antibiotics in Respiratory Infections in General Practice
NCT04216277 ·Status: WITHDRAWN ·Phase: NA
-
Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury
NCT04341038 ·Status: UNKNOWN ·Phase: PHASE3
-
Early Treatment Strategy With High-dose Dexamethasone in Patients With SARS-CoV-2
NCT05293210 ·Status: UNKNOWN ·Phase: PHASE3
-
Narrative Intervention for Long COVID-19 (NICO)
NCT06091293 ·Status: COMPLETED ·Phase: NA
-
Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia
NCT04469114 ·Status: COMPLETED ·Phase: PHASE3
-
Long-term Evolution of Pulmonary Involvement of Novel SARS-COV-2 Infection (COVID-19): Follow the Covid Study
NCT04605757 ·Status: UNKNOWN
-
Predictive Factors COVID-19 Patients
NCT04427345 ·Status: WITHDRAWN
-
Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection
NCT04344288 ·Status: TERMINATED ·Phase: PHASE2
-
Biomarkers for Dexamethasone Response in Sars-Cov-2 / COVID-19 Pneumonia
NCT04619693 ·Status: TERMINATED
-
Comparison of Two Corticosteroid Regimens for Post COVID-19 Diffuse Lung Disease
NCT04657484 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia
NCT04332913 ·Status: UNKNOWN
-
Early Short Course Corticosteroids in COVID-19
NCT04374071 ·Status: COMPLETED
-
Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit
NCT04853927 ·Status: WITHDRAWN ·Phase: PHASE3
-
Study to Investigate Long-term Pulmonary and Extrapulmonary Effects of COVID-19
NCT04581135 ·Status: COMPLETED
-
Clinical Outcome of Patients With COVID-19 Pneumonia Treated With Corticosteroids and Colchicine
NCT04654416 ·Status: COMPLETED
-
Corticosteroids Therapy and Pneumocystis Jirovecii Pneumonia (PCP)
NCT00636935 ·Status: WITHDRAWN ·Phase: PHASE4
-
Detection of SARS-CoV-2 RNA in Coughed Droplets From Patients With COVID-19
NCT04912895 ·Status: COMPLETED ·Phase: NA
-
Study Testing Convalescent Plasma vs Best Supportive Care
NCT04333251 ·Status: WITHDRAWN ·Phase: PHASE1
-
Risk Factors for COVID-19 Mortality
NCT04786808 ·Status: TERMINATED
-
Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia
NCT04334850 ·Status: COMPLETED ·Phase: NA
-
Clinical Characteristics And Outcome Of COVID-19 Infection In Patients With Chronic Respiratory Diseases.
NCT05054127 ·Status: UNKNOWN
-
Residual SARS-CoV-2 Presence in the Respiratory Tract and Lung Parenchyma (After SARS-CoV-2 Infection or COVID-19)
NCT04775134 ·Status: RECRUITING
-
TNF-alpha Antagonists for AECOPD: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial
NCT00789997 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Recovery of Respiratory System in COVID-19 Patients
NCT04954222 ·Status: COMPLETED